Proteasomal regulation of TNF-mediated local bone loss

TNF介导的局部骨质流失的蛋白酶体调节

基本信息

  • 批准号:
    7295764
  • 负责人:
  • 金额:
    $ 14.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-09-26 至 2009-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Chronic inflammatory bone diseases, such as rheumatoid arthritis, are characterized by local bone loss that is largely due to the effects of increased production of pro-inflammatory cytokines, IL-1, IL-6, and TNF. These cytokines cause enhanced osteoclastogenesis, and reduced osteoblast activity and survival. Although much is known about how cytokines stimulate focal osteoclastic bone erosion, the mechanisms by which cytokines inhibit osteoblast function remain unclear. In the past several years, the E3 ubiquitin ligase, Smad ubiquitin regulatory factor (Smurf1), has been reported to promote degradation of the osteoblast- specific transcription factor, Runx2, thereby inhibiting osteoblast differentiation. However, the regulation of Smurf and its role in the pathogenesis of inflammation-induced local bone loss have not been investigated. Recently, we have demonstrated that TNF stimulates Smurf1 expression in osteoblasts, which result in Runx2 degradation. TNF-mediated Runx2 degradation is associated with increased ubiquitination, which can be blocked by inhibitory RNA to Smurfl and proteasomal inhibitors. Consistent with this, tissues from joints of rheumatoid arthritic patients and TNF transgenic arthritic mice have high levels of Smurf1 and TNF expression. Based on these preliminary findings, we hypothesize that under inflammatory conditions, TNF or/and other cytokines inhibit osteoblast function through the up-regulation of Smurf-proteasomal degradation pathway. Here we propose to determine the effect of TNF on the Smurf pathway in osteoblasts in vitro, and the effect of Smurf1 deficiency on TNF-mediated osteoblast inhibition in vivo using TNF transgenic and Smurf1-/- mice. The overall purpose of this application is to validate the significance of the Smurf-proteasomal pathway in cytokine-mediated local bone loss. Results from this study should open up a new field of investigation into the involvement of Smurf E3 ligases in inflammation-mediated osteoblast inhibition in erosive bone diseases.
描述(由申请人提供):慢性炎性骨疾病,如类风湿性关节炎,其特征在于局部骨丢失,这主要是由于促炎细胞因子IL-1、IL-6和TNF产生增加的影响。这些细胞因子导致破骨细胞生成增强,成骨细胞活性和存活减少。尽管人们对细胞因子如何刺激局灶性破骨细胞性骨侵蚀已有很多了解,但细胞因子抑制成骨细胞功能的机制仍不清楚。在过去的几年中,E3泛素连接酶,Smad泛素调节因子(Smurf 1),已被报道促进成骨细胞特异性转录因子Runx 2的降解,从而抑制成骨细胞分化。然而,Smurf的调节及其在炎症诱导的局部骨丢失的发病机制中的作用尚未研究。最近,我们已经证明,TNF刺激Smurf 1在成骨细胞中的表达,导致Runx 2降解。TNF介导的Runx 2降解与增加的泛素化相关,这可以被Smurfl的抑制性RNA和蛋白酶体抑制剂阻断。与此一致,类风湿性关节炎患者和TNF转基因关节炎小鼠的关节组织具有高水平的Smurf 1和TNF表达。基于这些初步发现,我们推测在炎症条件下,TNF或/和其他细胞因子通过上调Smurf-蛋白酶体降解途径抑制成骨细胞功能。在这里,我们建议,以确定在体外成骨细胞的Smurf通路的TNF的影响,和在体内使用TNF转基因和Smurf 1-/-小鼠的Smurf 1缺陷对TNF介导的成骨细胞抑制的影响。本申请的总体目的是验证Smurf-蛋白酶体途径在苦参碱介导的局部骨丢失中的意义。这项研究的结果应该开辟了一个新的领域的调查参与Smurf E3连接酶炎症介导的成骨细胞抑制侵蚀性骨疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LIANPING XING其他文献

LIANPING XING的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LIANPING XING', 18)}}的其他基金

Synovial lymphatics and osteoarthritis in aging
衰老过程中的滑膜淋巴管和骨关节炎
  • 批准号:
    9884361
  • 财政年份:
    2020
  • 资助金额:
    $ 14.95万
  • 项目类别:
Synovial lymphatics and osteoarthritis in aging
衰老过程中的滑膜淋巴管和骨关节炎
  • 批准号:
    10544720
  • 财政年份:
    2020
  • 资助金额:
    $ 14.95万
  • 项目类别:
Synovial lymphatics and osteoarthritis in aging
衰老过程中的滑膜淋巴管和骨关节炎
  • 批准号:
    10319543
  • 财政年份:
    2020
  • 资助金额:
    $ 14.95万
  • 项目类别:
Study of osteoblast regulation in TNF-mediated bone loss
TNF介导的骨丢失中成骨细胞调节的研究
  • 批准号:
    9116770
  • 财政年份:
    2013
  • 资助金额:
    $ 14.95万
  • 项目类别:
Study of osteoblast regulation in TNF-mediated bone loss
TNF介导的骨丢失中成骨细胞调节的研究
  • 批准号:
    8631394
  • 财政年份:
    2013
  • 资助金额:
    $ 14.95万
  • 项目类别:
Role of TNFa in Osteoclast-Mediated Bone Loss
TNFa 在破骨细胞介导的骨丢失中的作用
  • 批准号:
    7929036
  • 财政年份:
    2009
  • 资助金额:
    $ 14.95万
  • 项目类别:
Proteasomal regulation of TNF-mediated local bone loss
TNF介导的局部骨质流失的蛋白酶体调节
  • 批准号:
    7197380
  • 财政年份:
    2006
  • 资助金额:
    $ 14.95万
  • 项目类别:
Role of TNFalpha in Osteoclast-Mediated Bone Loss
TNFα 在破骨细胞介导的骨丢失中的作用
  • 批准号:
    6792203
  • 财政年份:
    2002
  • 资助金额:
    $ 14.95万
  • 项目类别:
Role of TNFalpha in Osteoclast-Mediated Bone Loss
TNFα 在破骨细胞介导的骨丢失中的作用
  • 批准号:
    6465290
  • 财政年份:
    2002
  • 资助金额:
    $ 14.95万
  • 项目类别:
Role of TNFa in Osteoclast-Mediated Bone Loss
TNFa 在破骨细胞介导的骨丢失中的作用
  • 批准号:
    8080288
  • 财政年份:
    2002
  • 资助金额:
    $ 14.95万
  • 项目类别:

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
  • 批准号:
    31070748
  • 批准年份:
    2010
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目

相似海外基金

Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
  • 批准号:
    MR/Y009681/1
  • 财政年份:
    2024
  • 资助金额:
    $ 14.95万
  • 项目类别:
    Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
  • 批准号:
    MR/Y022947/1
  • 财政年份:
    2024
  • 资助金额:
    $ 14.95万
  • 项目类别:
    Research Grant
Preclinical development of an extracellular vesicle biotherapeutic for juvenile idiopathic arthritis
幼年特发性关节炎细胞外囊泡生物治疗药物的临床前开发
  • 批准号:
    10068495
  • 财政年份:
    2024
  • 资助金额:
    $ 14.95万
  • 项目类别:
    Collaborative R&D
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    $ 14.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Exploring the inflammatory mediators degraded by MMP-2 in MMP-2-deficient mice with knee arthritis through a novel TMT-TAILS quantitative proteomics
通过新型 TMT-TAILS 定量蛋白质组学探索 MMP-2 缺陷型膝关节炎小鼠中 MMP-2 降解的炎症介质
  • 批准号:
    24K19850
  • 财政年份:
    2024
  • 资助金额:
    $ 14.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
  • 批准号:
    491810
  • 财政年份:
    2023
  • 资助金额:
    $ 14.95万
  • 项目类别:
    Operating Grants
The role of diet, as mediated by the gut microbiome, on childhood arthritis disease activity: a feasibility intervention study.
肠道微生物组介导的饮食对儿童关节炎疾病活动的作用:一项可行性干预研究。
  • 批准号:
    489316
  • 财政年份:
    2023
  • 资助金额:
    $ 14.95万
  • 项目类别:
    Operating Grants
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
  • 批准号:
    EP/Y027760/1
  • 财政年份:
    2023
  • 资助金额:
    $ 14.95万
  • 项目类别:
    Fellowship
Investigation of hypoxia-inducible factor-1 (HIF-1) as a novel therapeutic target for juvenile idiopathic arthritis.
研究缺氧诱导因子-1 (HIF-1) 作为幼年特发性关节炎的新治疗靶点。
  • 批准号:
    23K14987
  • 财政年份:
    2023
  • 资助金额:
    $ 14.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel first-in-class Therapeutics for Rheumatoid Arthritis
类风湿关节炎的一流新疗法
  • 批准号:
    10696749
  • 财政年份:
    2023
  • 资助金额:
    $ 14.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了